Engineered immune cells take on autoimmune diseases in first human test
Disease control
Ongoing
This early-phase study tests a new treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing severe lupus or scleroderma. About 48 adults with these hard-to-treat autoimmune diseases will receive the therapy to see if it is…
Phase: PHASE1 • Sponsor: Synthekine • Aim: Disease control
Last updated May 14, 2026 12:03 UTC